

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 5-20 without prejudice to renewal.

Please enter the amendments to claims 1, 21, and 24-27, as shown below.

1. (Currently amended) A composition comprising an isolated apolipoprotein E (apoE) stable folding intermediate, wherein the apoE stable folding intermediate is at least [[about]] 80% pure, wherein the apoE is apoE3 or apoE4, and wherein the stable folding intermediate is formed at a pH of from [[about]] 1.0 to [[about]] 5.0.

2. (Canceled)

3. (Previously presented) The composition of claim 1, wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE4.

4. (Original) The composition of claim 3, wherein the N-terminal fragment of apoE4 is about 22 kDa in size.

5.-20. (Cancelled)

21. (Currently amended) The composition of claim 1, wherein the apoE stable folding intermediate is at least [[about]] 90% pure.

22. (Previously presented) The composition of claim 1, wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE3.

23. (Previously presented) The composition of claim 22, wherein the N-terminal fragment of apoE3 is about 22 kDa in size.

24. (Currently amended) The composition of claim 1, wherein the apoE stable folding intermediate is formed at a pH of from [[about]] 2.0 to [[about]] 4.0.

25. (Currently amended) The composition of claim 1, wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 2M to [[about]] 7M.

26. (Currently amended) The composition of claim 1, wherein the apoE is apoE4, and wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 3.5 M to [[about]] 4.5 M.

27. (Currently amended) The composition of claim 1, wherein the apoE is apoE3, and wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 4.5 M to [[about]] 5 M.